EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2024-2032

In the United Kingdom, the market is driven by a robust healthcare infrastructure, along with increasing government focus on dementia research and early diagnosis. The National Health Service (NHS) and various research initiatives contribute to advancing diagnostic technologies and the availability of therapeutics, positioning the UK as a key player in the Alzheimer’s market.

Germany, with its strong emphasis on medical innovation and research, is a major contributor to the Alzheimer’s disease therapeutics & diagnostics sector. The country benefits from its advanced healthcare system, which facilitates early detection and treatment options for Alzheimer’s disease. Additionally, the growing demand for disease-modifying therapies and diagnostic tools, coupled with Germany’s leadership in the pharmaceutical and biotechnology industries, ensures continued market growth and development in the country.

In France, the market is expanding due to a rising aging population and a concerted push for better dementia care. France has been making vital investments in research, with numerous clinical trials and initiatives aimed at improving early diagnosis and treatment options. The country’s commitment to improving healthcare outcomes for Alzheimer’s patients, combined with its growing focus on personalized medicine, further supports the market’s growth in the region.

The Europe Alzheimer’s disease therapeutics & diagnostics market segmentation includes the market by product. The product segment is further differentiated into therapeutics (including cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics) as well as diagnostics (including brain imaging, CSF test for Alzheimer’s disease, and other diagnostics). 

Other therapeutics for Alzheimer’s disease focus on disease-modifying treatments that target the underlying causes of the condition rather than just alleviating symptoms. One of the key approaches includes monoclonal antibodies, which are designed to target amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease. Drugs like aducanumab and lecanemab are part of this class, and they work by reducing the buildup of amyloid plaques, which is believed to slow disease progression. These therapies aim to delay the cognitive decline associated with Alzheimer’s and provide a potential for long-term management.

Additionally, tau-targeted therapies are another promising area in Alzheimer’s treatment. These drugs aim to prevent the formation of tau tangles, another hallmark of the disease. By targeting tau, these treatments hope to protect the brain from neurodegeneration and preserve cognitive function. Other research is exploring anti-inflammatory and neuroprotective agents to address brain inflammation and protect neurons from further damage. As these therapies develop, they have the potential to provide a more comprehensive approach to treating Alzheimer’s disease, improving outcomes for patients, particularly in the early to moderate stages of the condition.

Some of the leading players in the Europe Alzheimer’s disease therapeutics & diagnostics market include Allergan PLC (acquired by AbbVie), Biogen Inc, Cognoptix Inc, etc.

Allergan PLC, headquartered in Dublin, Ireland, operates in numerous countries, including the United States, Canada, China, India, and several high-growth markets across Europe, Southeast Asia, the Middle East, and Latin America. The company specializes in developing, manufacturing, marketing, and distributing branded biosimilar and over-the-counter (OTC) products. Moreover, in May 2020, AbbVie completed its acquisition of Allergan, and it is now part of AbbVie.